HHS Secretary Kennedy Appoints Two OB-GYN Experts to CDC's ACIP
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: seekingalpha
- New Member Appointments: HHS Secretary Robert F. Kennedy appointed two OB-GYN experts, Adam Urato and Kimberly Biss, to the CDC's Advisory Committee on Immunization Practices, enhancing the committee's scientific and clinical expertise.
- Committee Expansion: This appointment increases the ACIP membership to 12, nearing the maximum of 19, reflecting a commitment to immunization policy ahead of the upcoming September meeting.
- Policy Impact: ACIP meets three times a year to provide non-binding recommendations to the CDC on immunization policy, directly influencing vaccine coverage and costs for the American public, ensuring vaccine accessibility.
- Historical Context: Kennedy dismissed all 17 ACIP members in June 2025 due to conflicts of interest, subsequently appointing eight new members, demonstrating a commitment to rigorous scrutiny and restructuring of the committee's membership.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 93.990
Low
95.00
Averages
102.75
High
108.00
Current: 93.990
Low
95.00
Averages
102.75
High
108.00
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
